A biomarker-based platform for early diagnosis of chronic liver disease to enable personalized therapy


Liver diseases kill some 300 000 people in Europe every year. Some of the biggest risk factors for liver disease are obesity, type 2 diabetes, and alcohol consumption, and as all of these are on the rise, cases of liver disease are likely to increase as well in the coming decades.

Many liver diseases are ‘silent’ in the early stages, and by the time people develop symptoms and seek medical help, their liver may be irreversibly damaged, meaning a liver transplant is the only effective treatment. If we could detect cases of liver disease early on, further damage could be prevented and in some cases, existing damage could even be reversed.

The LIVERAIM project’s overall goal is to set up a screening platform to detect cases of liver disease early on, so that patients can take steps to protect their liver before it’s too late. As the silent phase of the disease can last for two decades, there is a clear window of opportunity to take action here.

Previous research has found a number of biological markers of liver damage, but they have not yet been tested in large numbers of people in the general population. LIVERAIM will take biological samples and data from earlier projects (including the IMI project LITMUS) and use them to evaluate the ability of these biomarkers to detect which patients have liver damage and which do not. The results of this work will be analysed using standard statistics and artificial intelligence (AI) with the goal of developing a biomarker platform.

The platform will then be validated in a randomised clinical trial to prove the benefit of a screening programme. People diagnosed with liver disease will receive personalised advice designed to halt the progress of the disease. For the majority of patients whose liver disease is linked to factors such as obesity and alcohol use, the advice and support will focus on helping patients to change their lifestyle.

Ultimately, by helping patients to protect their livers, LIVERAIM will help to reduce the burden of liver disease on patients, their families, and health systems.


  Show participants on map
Universities, research organisations, public bodies, non-profit groups
  • European Association For The Studyof The Liver, Zürich, Switzerland
  • Fakultna Nemocnica S Poliklinikou F.D. Roosevelta Banska Bystrica, Banska Bystrica, Slovakia
  • Fondation Cardiometabolisme Nutrition, Paris, France
  • Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer, Barcelona, Spain
  • Fundacion Privada Instituto De Salud Global Barcelona, Barcelona, Spain
  • Mayo Clinic, Rochester, United States
  • Region Syddanmark, Vejle, Denmark
  • Sveuciliste U Zagrebu Medicinski Fakultet, Zagreb, Croatia
  • Universita Degli Studi Di Padova, Padova, Italy
  • Universita Degli Studi Di Torino, Turin, Italy
  • Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany
  • Universitat Autonoma De Barcelona, Bellaterra, Spain
  • Universitat De Barcelona, Barcelona, Spain
  • Universitat Des Saarlandes, Saarbruecken, Germany
  • Universitat Zurich, Zürich, Switzerland
  • University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Innovation Acta SRL, Roma, Italy
Patient organisations
  • European Liver Patients Association, Bruxelles, Belgium
Third parties
  • Assistance Publique Hopitaux De Paris, Paris, France
  • Azienda Ospedale Universita Padova, Padova, Italy
  • Hospital Clinic De Barcelona, Barcelona, Spain
  • Klinicka Bolnica Dubrava Zagreb, Zagreb, Croatia
IHI industry partners
  • Astrazeneca AB, Södertälje, Sweden
  • Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany
  • Echosens, Paris, France
  • Gilead Sciences Ireland Uc, Carrigtoohill, Ireland
  • Nordic Bioscience A/S, Herlev, Denmark
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Roche Diagnostics International AG, Rotkreuz, Switzerland
  • Siemens Healthcare GMBH, Erlangen, Germany
  • Sysmex Europe Se, Norderstedt, Germany

NameEU funding in €
European Liver Patients Association125 000
Fakultna Nemocnica S Poliklinikou F.D. Roosevelta Banska Bystrica759 720
Fondation Cardiometabolisme Nutrition358 125
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer2 874 898
Fundacion Privada Instituto De Salud Global Barcelona1 147 454
Innovation Acta SRL499 555
Nordic Bioscience A/S200 000
Region Syddanmark2 248 769
Sveuciliste U Zagrebu Medicinski Fakultet221 053
Universita Degli Studi Di Padova500 344
Universita Degli Studi Di Torino660 500
Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz342 500
Universitat Autonoma De Barcelona721 444
Universitat De Barcelona471 041
Universitat Des Saarlandes983 347
Third parties
NameFunding in €
Assistance Publique Hopitaux De Paris182 188
Azienda Ospedale Universita Padova666 250
Hospital Clinic De Barcelona265 317
Klinicka Bolnica Dubrava Zagreb627 088
Total Cost13 854 593